Androgen deprivation therapy is frequently used to treat patients with advanced prostate cancer.
New therapies for metastatic castration-resistant prostate cancer have drawn increased attention to serum and intratumoral testosterone levels. The present review examines the role of testosterone in prostate cancer progression, discusses the nuances and potential pitfalls in measuring serum testosterone using available assays, and summarizes current data relevant to the arguments for and against achieving and maintaining the lowest possible testosterone levels during androgen deprivation therapy, including the adverse effects of such treatment. Incorporating this information, we have made recommendations incorporating testosterone evaluation and its effect on the clinical decision-making process.
Written by:
Rove KO, Debruyne FM, Djavan B, Gomella LG, Koul HK, Lucia MS, Petrylak DP, Shore ND, Stone NN, Crawford ED. Are you the author?
University of Colorado Denver, Anschutz Medical Campus, Aurora, CO.
Reference: Urology. 2012 Jul 12. Epub ahead of print.
doi: 10.1016/j.urology.2012.05.006
PubMed Abstract
PMID: 22795376
UroToday.com Prostate Cancer Section
